Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 776

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 776
---
 -03, Disaggregation of Income Statement Expenses (“DISE”), a new accounting standard to improve the disclosures about an entity’s expenses and address requests from investors for more detailed information about the types of expenses included in commonly presented expense captions. The new standard is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with retrospective application permitted. The Company is evaluating the disclosure requirements related to the new standard and its impact on the Company’s consolidated financial statements. The Company has implemented all new accounting pronouncements currently in effect that may impact its consolidated financial statements and does not believe any other recently issued standards will have a material impact on its financial position or results of operations. Annex F-15 NLS PHARMACEUTICS LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 3

Prepaid Expenses and Other Current Assets:

The Company’s prepaid expenses and other current assets consisted of the following as of December 31, 2024, and 2023:

|                                                 |     | December 31, |    2024 |     |   |    2023 |
|:------------------------------------------------|:----|:-------------|--------:|:----|:--|--------:|
| Vendor prepayments                              |     | $            |  65,237 |     | $ | 821,266 |
| VAT recoverable and other current assets        |     |              |  49,479 |     |   |  24,433 |
| Other short-term receivables                    |     |              | 400,000 |     |   |  10,664 |
| Prepaid insurance                               |     |              |  42,470 |     |   |  69,019 |
| Prepaid expenses                                |     |              |   2,970 |     |   |       — |
| Total prepaid expenses and other current assets |     | $            | 560,157 |     | $ | 925,382 |

During the period ended December 31, 2024, the Company provided working capital advances totaling $ to Kadimastem, a third party with which the Company is engaged in merger negotiations. These funds were provided to support Kadimastem’s ongoing operations and are recorded as Other Receivable on the balance sheet. The funds are repayable on demand or upon termination of the merger discussions. If the merger is